Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Heart drug

    - PMLiVE

    Novartis agrees to lower drug prices in deal with US government

    In 2025, the pharma company announced a $23bn US investment commitment

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

    Over 800,000 people worldwide live with haemophilia

    - PMLiVE

    AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

    In 2022, nearly one million new patients were diagnosed with gastric cancer

    - PMLiVE

    Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

    Around 9,000 people in the US currently live with SMA

    - PMLiVE

    Novartis announces plans for new US manufacturing hub

    The US hub is expected to create 700 new jobs by 2030

    - PMLiVE

    Pfizer’s PADCEV gets FDA approval for bladder cancer

    Bladder cancer affects more than 614,000 people globally each year

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    Novartis reports primary endpoint reached in phase 3 malaria trial

    The treatment demonstrated non-inferiority to current standard of care

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    AstraZeneca reports positive results from phase 3 blood pressure trial

    The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

    - PMLiVE

    Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

    The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links